Stryker (SYK) revenue breakdown
By segment, MedSurg and Neurotechnology is the largest at 62% of fiscal 2025 revenue, growing 11% a year over 6 years.
By region, United States is the largest at 76% of fiscal 2025 revenue, growing 10% a year over 9 years.
Revenue by segment
Fiscal years, as Stryker reports them in its 10-K filings; fiscal 2025 total $25.1B.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology | — | — | — | $8.5B | $8.3B | $9.5B | $10.9B | $12.2B | $13.5B | $15.6B | 62% |
| Orthopaedics | — | — | — | $6.4B | $6.0B | $7.6B | $7.6B | $8.3B | $9.1B | $9.5B | 38% |
| MedSurg | $4.9B | $5.6B | $6.0B | — | — | — | — | — | — | — | — |
| Orthopaedics | $4.4B | $4.7B | $5.0B | — | — | — | — | — | — | — | — |
| Neurotechnology and Spine | $2.0B | $2.2B | $2.6B | — | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Stryker reports them in its 10-K filings; fiscal 2025 total $25.1B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $8.2B | $9.1B | $9.8B | $11.0B | $10.5B | $12.3B | $13.6B | $15.3B | $16.9B | $19.0B | 76% |
| Europe, Middle East, Africa | $1.4B | $1.6B | $1.8B | $1.9B | $1.8B | $2.3B | $2.3B | $2.6B | $2.9B | $3.2B | 13% |
| Asia Pacific | $1.3B | $1.4B | $1.5B | $1.6B | $1.6B | $2.0B | $1.9B | $1.9B | $2.0B | $2.2B | 9% |
| Other foreign countries | $333M | $405M | $428M | $422M | $448M | $515M | $578M | $677M | $735M | $765M | 3% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for SYK.
Open SYK in InvestinglyQuestions
Where does Stryker make its money?
In fiscal 2025, by segment: MedSurg and Neurotechnology $15.6B, Orthopaedics $9.5B.
From Stryker's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.